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Abstract
Introduction:Microglial cells play an important role in the development of Alzheimer’s
disease (AD). PeoplewithDown syndrome (DS) inevitably developADneuropathology
(DSAD) by 40 years of age. We characterized the distribution of different microglial
phenotypes in the brains of people with DS andDSAD.
Methods: Autopsy tissue from the posterior cingulate cortex (PCC) from people with
DS, DSAD, and neurotypical controls was immunostained with the microglial marker
Iba1 to assess fivemicroglia morphological types.
Results: IndividualswithDShavemorehypertrophicmicroglial cells in theirwhitemat-
ter. In the graymatter, individualswithDSADhad significantly fewer ramifiedmicroglia
and more dystrophic microglia than controls and the younger individuals with DS. The
DSAD group also exhibitedmore rod-shaped and amoeboid cells than the AD group.
Discussion: Individuals with DS and DSAD show a microglial phenotype that distin-
guishes them from non-DS controls.
KEYWORDS
IBA-1, microglial morphology, neuroinflammation, posterior cingulate cortex, trisomy 21
1 INTRODUCTION
Down syndrome (DS) or trisomy 21 is the most common genetic cause
of intellectual disability. While improvements in medical care along
This is an open access article under the terms of the Creative Commons Attribution-NonCommercial License, which permits use, distribution and reproduction in any
medium, provided the original work is properly cited and is not used for commercial purposes.
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with social enrichment in DS has led to a significant extension in lifes-
pan and increased quality of life, it has also increased the prevalence
of Alzheimer’s disease (AD). Further, the overexpression of the amy-
loid beta (Aβ) precursor protein (APP) gene, located on chromosome
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21, leads to an enhanced production of Aβ1 and is likely to be one
of the main causes for the increased risk of AD in this population.2–4
As a result, by 40 years of age the majority of people with trisomy
21 have sufficient numbers of Aβ plaques and neurofibrillary tangles
for a neuropathological diagnosis of AD. Notably, alterations in blood
and cerebrospinal fluid (CSF) biomarkers consistent with changes in
familial and sporadic AD are also found in people with DS.5–9 It is
estimated that 55% of individuals with DS between the ages of 40 to
49 showprogressive cognitive impairment,while in individuals aged60
to 69 this prevalence increases to 77%;10,11 thus, there is a temporal
disconnect between age when AD neuropathology is present and the
presence of clinical symptoms of dementia.11,12 A unique advantage to
studyingAD in peoplewithDS is that there is a distinct age-related pat-
tern of neuropathology that may allow us to investigate and determine
the first appearance of alterations in specific pathways or cells.2
Neuroinflammation may be a key causative factor in the patho-
genesis of AD in DS.13–17 In the frontal cortex of people with DS and
dementia, there is a dysregulation of numerous genes related to Aβ
and tau biology, as well as other fundamental pathways related to
intracellular signaling, cell homeostasis, and death, and the cholinergic
and glutamatergic systems, among others, suggesting a specific genetic
profile implicating cortical dysfunction in demented individuals with
DS.18 Interestingly, the dysregulation of immune-related genes indi-
cate an inflammatory state in the adult brain, as these genes are not
altered in fetal brains, and could be directly linked to the development
of AD pathology in DS.19 There are at least six genes on chromosome
21 thatmay contribute to increased inflammation inDS.16 Both human
DS and DS mouse models present with marked neuroinflammation,
with the activation of both microglia and astrocytes.14,20,21 In adults
with DS there is a correlation between inflammatory markers and
other AD biomarkers as well as an increase in the circulating levels of
inflammatory cytokines in blood.22,23 In previous autopsy studies, we
noted that the inflammatory phenotype of people with DS is different
from age-matched neurotypical controls reflecting an increase in
pro-inflammatory gene expression like interleukin (IL)-6 and IL-12.
In the presence of AD neuropathology in the DS (DSAD) brain, there
is additional inflammation present that overlaps with that seen in
sporadic AD.15 However, elevated CD86 and FcgR1 is observed in
DSAD,which is different from sporadic AD, and suggests extravasation
of serum proteins into the brain that may promote the formation of
immune complexes. Consistent with increased inflammation in DS, our
initial studies of microglial activation, using HLA-DR immunostaining,
showed higher microglial loads in DSAD relative to DS and controls,15
consistent with reports in sporadic AD.24
Microglial cells play an important role in AD development, with evi-
dence evolving from studies of their close interaction with plaques and
tangles, an increased risk of AD due to polymorphisms in microglial-
expressed genes such as TREM2 and CD33, as well as changes in
their morphology in the presence of AD pathology.25–27 Microglia
morphology in humans can range from ramified to amoeboid cells.
While a ramified shape is characterized by a small, round cell body
with extended long branching processes, amoeboid microglia are at
the extreme end of the spectrum with a large round cell body, rich in
HIGHLIGHTS
∙ Hypertrophic microglial cell numbers increase with age in
the white matter.
∙ Numbers of ramified microglia are lower with age in the
graymatter in people with DS and controls.
∙ People with DS and AD neuropathology have more dys-
trophic cells in the graymatter.
∙ People with DSAD have more rod-shaped and amoeboid
cells than controls.
RESEARCH INCONTEXT
1. Systematic Review: We reviewed the literature using
PubMed. We searched for research studies describing
microglial changes and characterization in autopsy tissue
from brains of people with Down syndrome (DS) and/or
Alzheimer’s disease (AD), and these have been appropri-
ately cited.
2. Interpretation: Our findings demonstrate that people
with DS, and particularly those with Alzheimer’s disease
pathology (DSAD), present a microglial phenotype pat-
tern that distinguishes them from non-DS controls. In
DSAD there are more dystrophic and fewer ramified
microglial cells, suggesting more damage to microglia.
Further, it reinforces the differences seen in individ-
uals with DS with regard to their neuroinflammation
response.
3. Future Directions: More studies are necessary to fully
evaluate the role of each specific microglial phenotype in
DS, and to understand the microglial pathways that con-
tribute to the development and progression of AD in indi-
viduals with DS.
cytoplasm and without processes. Changes in microglial morphology
and motility can be exacerbated in AD and other pathologies, which
reflect the functional state of the cell, and potentially contribute to the
development and progression of the disease.28,29
Microglial morphology in DS, particularly in people with DSAD,
remains largely unexplored. The first description of differences in
microglia in DS reported significantly more IL-1 positive microglia
in brain tissue from young people with DS relative to age-matched
controls (postnatal to 41 years of age).30 Moreover, a reduced number
of resting microglia is accompanied by increased dystrophic microglial
cells in a small study of autopsy cases with DS over 40 years of age.31
Thus, the current study was intended to expand upon these studies
and explore microglial morphology responses in the brains of people
with DS with or without AD across the lifespan, with a focus on the
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TABLE 1 Case characteristics for posterior cingulate cortex tissue obtained from brain banks
YC DS MC DSAD AC AD
N 11 10 10 17 6 6
Age at death, years 17.89
(11.83)
19.5
(15.54)
53.5
(6.65)
57.00
(8.28)
78.67
(2.16)
78.83
(1.83)
Male/female, n/n 9/2 7/3 6/4 8/9 3/3 4/2
Post mortem interval (PMI), hours 20.45
(5.05)
19.3
(6.15)
16.2
(6.78)
5.98
(6.41)
9.00
(6.54)
12.86
(10.13)
Abbreviations: AC, aged control; AD, sporadic Alzheimer’s disease;DS,Down syndrome;DSAD,Down syndromewith neuropathological Alzheimer’s disease;
MC, middle-aged control; YC, young control.
Note:Mean+ standard deviation.
posterior cingulate cortex (PCC). The rationale for selecting the PCC
is three-fold. First, older individuals with DS show lower glucose
metabolic rates in the PCC relative to their control groups.32 Second,
the PCC, along with the precuneus and posterior parietotemporal
lobes, is also one of the earliest sites of reduced glucose metabolism
(fluorodeoxyglucose positron emission tomography) before the
appearance of symptoms in sporadic AD, which can lead to neuronal
and synaptic loss.33 Third, neuronal health biomarkers in this region
are lower as measured by magnetic resonance spectroscopy, while
glial biomarkers are significantly higher, in demented adults with DS.34
To further characterize microglia phenotypic changes in DS, we used
Iba1 (ionized calcium binding adaptor molecule 1) immunostaining
that labels all microglia cells and their processes, allowing for a better
characterization of theirmorphology. Thus, the aim of this studywas to
characterize the distribution of different microglial phenotypes in the
brains of people with DS and DSAD relative to age-matched controls,
and late onset AD.
2 METHODS
2.1 Human tissue samples
Fixed tissue samples were acquired from the PCC (Brodmann area 23
and 31) from the tissue repositories located at the Alzheimer’s Disease
Research Center at the University of California Irvine, the NIH Neu-
roBioBank, and the University of Kentucky Alzheimer’s Disease Cen-
ter. Human tissue collection and handling adhered to the University
of Kentucky and University of California, Irvine, Institutional Review
Board guidelines. Neuropathologic diagnosis of AD was in accordance
with currentNational Institute onAging-Alzheimer’s Association (NIA-
AA) guidelines.35,36 Cases from the University of California Irvine
were fixed in 4% paraformaldehyde, while cases from the NIH Neuro-
BioBank and the University of Kentucky were fixed in 10% formalin. A
solution of phosphate buffered saline (PBS) with 0.02% sodium azide
was used for long-term storage. No information regarding the length
of fixation is available.
Six autopsy groups were included in this study (Table 1): young
controls (YC; age-matched to young DS group; n = 10), middle-aged
controls (MC; age-matched to Down syndrome-Alzheimer’s disease
group; n = 10), aged controls (AC; age-matched to AD group; n = 6),
Down syndrome (DS, n = 10), Down syndrome with neuropatholog-
ical AD (DSAD, n = 17), and sporadic AD (AD, n = 6). DSAD are DS
cases that had sufficient neuropathology for a post mortem diagnosis
of AD, according to Hyman et al.35 Because people with DSAD come
to autopsy at younger ages than those with sporadic AD, we were not
able tomatch for age between these two groups. All control caseswere
selected to match for post mortem interval (PMI) to the DS, DSAD, and
AD cases. Our groups contained both males and females, but due to
the limited availability of cases, we were not able to match for sex
across groups. Clinical data were not incorporated into the present
study.
2.2 Immunohistochemistry
Tissue was sectioned on a vibratome (Leica Biosystems, Buffalo Grove,
Illinois, USA) at 50μm. Sequential sectionswere collected and stored in
PBS with 0.02% sodium azide until used. Following standard immuno-
histochemistry protocols and using Iba-1 antibody (Abcam, Cam-
bridge, Massachusetts, USA; 1:800) the sections were incubated in
the primary antibody overnight and followed by incubation in an
anti-rabbit secondary antibody (Vector Laboratories, Burlingame, Cal-
ifornia, USA). This was followed by amplification of the signal using
an avidin-biotin complex peroxidase kit, and 3,3′ diaminobenzidine
substrate kit. After immunohistochemistry, each tissue section was
mounted on a glass slide and coverslippedwithDepexmountingmedia.
All tissue sections were immunostained within a single experiment to
reduce variability.
2.3 Image analysis
The Aperio ScanScope XT digital slidescanner was used to scan the
entire slide at 20xmagnification. TheAperio ImageScope (v11.1.2.752)
software was used to draw five random 250 × 250micron boxes in the
white matter (WM) and five random 250 × 250 micron boxes in the
gray matter (GM) for each tissue section (Figure 1A). Five microglia
morphological types were assessed, as defined in previous work and
illustrated in Figure 1B–F37–40: (B) ramified microglia, which have thin,
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F IGURE 1 Microglia morphologies evaluated in the posterior cingulate cortex, andmicroglia cell counts in the Alzheimer’s disease (AD) brain.
A, Characterization of microglia was performed in five random 250× 250micron boxes in the white matter and five random 250× 250micron
boxes in the graymatter for each tissue section Scale: 3 μm. Fivemicroglia morphologies were analyzed: (B) ramifiedmicroglia, which have thin,
branched processes to actively “survey” changes in their environment; (C) hypertrophic microglia (also known as activatedmicroglia), whichmay
have enlarged, short processes and thicker bodies; (D) dystrophic microglia, that present fragmented or “beaded” processes possibly due to
microglial dysfunction as a result of aging; (E) rod-shapedmicroglia, that have elongated nuclei, few processes, and aremost notable in chronic
disorders; (F) amoeboidmicroglia, which have a round body, lack processes, and appear in response to acute destruction of central nervous system
tissue. Scale: 5 μm. G–K, In the whitematter, no significant changes were observed in any of themicroglial phenotypes analyzed. In the graymatter,
a significant reductionwas observed in the number of ramified cells in the AD group, while the number of dystrophic cells was increased, compared
to aged controls. Data are presented asmean± standard error of themean, * P≤ 0.05 (Student’s t test)
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branched processes that are thought to actively “survey” changes in
their environments; (C) hypertrophic microglia (also known as acti-
vatedmicroglia), whichmay have enlarged, short processes and thicker
bodies; (D) dystrophicmicroglia that have fragmented or “beaded” pro-
cesses possibly due to microglial dysfunction due to aging 41,42; (E)
rod-shaped microglia that have elongated nuclei, few processes, and
are most notable in chronic disorders; and (F) amoeboid microglia that
have a round body, may lack processes, and appear in response to
acutedestructionof central nervous system tissue. Thenumberof ram-
ified, hypertrophic, dystrophic, rod-shaped, and amoeboid microglia
in each annotation box was counted by hand and averaged for each
case, separating WM and GM. The categorical analysis used to quan-
tify themicroglia expanded upon previously established guidelines and
figures.38,43,44 Counts were made by two investigators blinded to all
samples groups and case histories. Cohen’s κ was run to determine
whether there was agreement between investigators.
2.4 Statistics
IBMSPSS Statistics Software (Version 24)was used for statistical anal-
ysis. Overall group differences were assessed for the GM and WM
separately using a two-way analysis of variance to examine interac-
tions between age groups and genotype (DS vs non-DS). Comparisons
between two groups were made using Student’s t test. Differences
between means were considered significant at P ≤ .05. Graphs were
generated using GraphPad Prism software version 8.0, with values
expressed asmean± standard error of themean.
3 RESULTS
3.1 Microglial phenotypes in AD versus
age-matched controls
Quantification of Iba1-positive cells in the GM of patients with AD
demonstrate a significant decrease of ramified cells, while dystrophic
cells are increased, compared to age-matched controls (Figure 1G,
I, respectively), consistent with previous reports.38,40,42,45 Also, the
numbers of hypertrophic microglia did not vary significantly across
groups (Figure 1H) nor did the numbers of rod-shaped or amoeboid
cells (Figure 1J, K), highlighting the robustness and reliability of the
methodology used in this study.
3.2 Microglial morphology differences with age
and genotypes
Age and the presence of AD pathology are completely intertwined in
DS. By 40 years of age, virtually all adults withDS have enough neuritic
plaques and neurofibrillary tangles for a diagnosis of AD pathology.2,46
Deposition of Aβ happens decades earlier in DS, compared to aged-
matched controls and AD brains.1 Thus, we believe that our rationale
of comparing DSAD with middle-aged controls without controlling for
age is the most appropriate way to conduct these analyses. Comparing
DS to DSADwhile controlling for age would eliminate all possible out-
comes as the DSAD are always older than the DS group.
Therefore, inPCCWM, thenumberof hypertrophicmicroglia is con-
sistently higher in DS groups (main effect of genotype, independent of
age [F(1,46) = 6.239, P = .016]), but none of the other microglial phe-
notypes are significantly different (Figure 2A).
In the GM, both age group and genotype have different effects
for individual microglial phenotypes. Comparing ramified microglial
counts, we find a main effect of age group independent of genotype
(F[1,46]= 5.827, P= 0.020), reflecting an overall decrease in the num-
bers of ramified microglial cells independent of the presence of DS
(Figure 2B). While the number of ramified cells is lower in cases over
40 years of age, dystrophic microglia counts are higher, demonstrat-
ing also a significant effect of age independent of genotype in the gray
matter of PCC (F[1,46] = 4.488, P = 0.04). The amoeboid cell quantifi-
cation demonstrate a main effect of genotype overall (F[1,46]= 5.645,
P= 0.022) as well as age (F[1,46]= 3.868, P= 0.056), and a significant
interactionbetweenageandgenotype (F[1,46]=6.449,P=0.015). The
number of amoeboid cells was higher inDS overall and primarily driven
by high numbers in DSADPCC.
3.3 Microglial morphology in DS
Given that we cannot separate age from the presence of AD neu-
ropathology in DS, we compared four groups divided between geno-
type (DS vs control) and age group (<40 vs >40 years), reflecting
absence and presence of AD neuropathology, respectively (Figure 3).
No significant differences were found in the WM between the
groups (Figure3A -E). In theGM,DSADwas associatedwith the fewest
numbers of ramified microglial cells, both in comparison to MC (P =
0.023) orDS (P=0.009) (Figure 3A).While the number of ramified cells
is lower in cases over 40 years of age, dystrophic microglia counts are
higher in the DSAD group when compared to the DS group (P= 0.007)
and middle-aged controls (P = 0.019; Figure 3C). The average num-
ber of rod-shaped cells is consistently low, so the apparent increase in
DSAD groups is not sufficient to achieve statistical significance (Figure
3D). Counts for amoeboidmicroglia are also consistently low across all
groups; however, higher numbers of amoeboidmicroglia are present in
a subset of our DSAD cases . While we found a significant increase in
the number of amoeboid cells overall in theDSAD group in comparison
to the DS group (P = 0.008) and middle-aged controls (P = 0.003), the
numbers of these cells are low and this result needs to be cautiously
interpreted (Figure 3E).
3.4 Microglial phenotype comparing DSAD
and sporadic AD
No significant differences are observed for any of the microglial phe-
notypes in the WM comparing DSAD to AD (Figure 4). Further, the
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F IGURE 2 Distribution of microglia phenotypes across different groups in white and graymatter. The average number of microglia in each of
the five classifications according to each group in the white (A) and gray (B) matter, demonstrating the age and genotype effects related to the
morphology of cells. Data are presented asmeans. A, In the white matter, hypertrophic microglia increase as amain effect of genotype. B, In the
graymatter, the age effect is significant for ramified and dystrophic cells. Amoeboid cells have an effect of age, genotype, and a significant
interaction between these factors
numbers of ramified, hypertrophic, and dystrophic microglia were sim-
ilar across groups (Figure 4A–C). There are, however, individual DSAD
cases that have higher numbers of ramified and dystrophic microglia.
Consistent with the literature,38,47 few rod-shaped microglia were
found, thus the average counts are relatively low. Interestingly, in the
GM of DSAD cases there are more rod-shaped cells (P = 0.0387) com-
pared to AD cases (Figure 4D). Moreover, DSAD also presents with
more amoeboid cells than the AD group (P= 0.0009; Figure 4E).
4 DISCUSSION
The aim of this study was to characterize the distribution of differ-
ent microglial phenotypes in the brains of people with DS and DSAD.
We used autopsy tissue from the PCC to characterize microglia in the
white and gray matter by manually assessing morphology based upon
immunostaining with Iba1, a marker of all microglia cells and their pro-
cesses.
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F IGURE 3 Characterization of microglia phenotypes in the white and graymatter in Down syndrome (DS) groups. Microglial counts are
provided for the white (WM) and graymatter (GM) for (A) ramified, (B) hypertrophic, (C) dystrophic, (D) rod-shaped, and (E) amoeboid
morphologies. No significant changes were observed in any of themicroglial phenotypes analyzed in the white matter. In the graymatter, the DS
with neuropathological Alzheimer’s disease group presented a significant reduction in the number of ramified cells and an increase in the counts of
dystrophic and amoeboid cells, when compared to DS andmiddle-aged control groups. Data are presented asmean± standard error of themean, *
P≤ .05 (two-way analysis of variance)
In our study, we observe a significant genotype effect (DS vs non-
DS) in the number of hypertrophic microglia in theWM. Hypertrophic
microglia have enlarged, short processes, and thicker bodies, and are
thought to be actively responding to injury.38,40 This increase in hyper-
trophic microglia contrasts with other published findings on microglia
in DS, which show individuals with DS having fewer hypertrophic
microglia than controls.31 However, these studies were focused on the
GM in the temporal cortex, highlighting the importance of examining
both the white and gray matter. In addition to a unique inflammatory
response, people with DS also show a significant reduction in WM
integrity compared to controls.48 Moreover, significant vascular
pathology is also observed with increasing age in DS, which could also
potentially elicit hypertrophied microglial cells observed in the WM
in our study.49,50 Our results do not demonstrate significant changes
in any of the other microglial phenotypes in the WM, which could be
due to lower numbers overall, leading to a floor effect. Interestingly,
we observed an increase, although not significant, in the number of
dystrophic cells in the WM of all groups, including young controls.
Microglia is a dynamic cell that can adapt and change its morphology
according to different pathological situations.51 In our study, different
causes of death could potentially explain the pattern changes observed
in young groups; unfortunately, this information is not available for
further investigation. Observations in our caseswithDS are consistent
with studies in other autopsy series of AD. Recent studies shed some
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F IGURE 4 Down syndromewith neuropathological Alzheimer’s disease (DSAD) presents more rod-shaped and amoeboid cells than AD.
Differences in microglial counts for the white matter (WM) and graymatter (GM) betweenDSAD and AD groups are shown for (A) ramified, (B)
hypertrophic, (C) dystrophic, (D) rod-shaped, and (E) amoeboid phenotypes.While no significant changes were seen in theWM, the DSAD group
presented significant increase in the number of rod-shaped and amoeboidmicroglia cells in the GM, compared to AD alone. Data are presented as
mean± standard error of themean, * P≤ 0.05 (Student’s t test)
light into aspects of WM changes during aging, where activated
microglia respond to age-related pathologic changes,52 and microglia
proteins increase in an age-dependent manner already in middle-aged
people.53 Evenmore interesting is the detection of increasedmicroglia
activity in theWMof human post mortem early-onset AD (EOAD) brain
tissue, detected through non-invasive positron emission tomography
imaging using [11C]-(R)-PK11195, a ligand that binds to activated
microglia.53 Findings from other studies demonstrate a relationship
between the increase of activated microglia in the WM and GM
atrophy in other dementias,54 suggesting abnormalities in WM as an
early event preceding GM atrophy, especially in EOAD.55
We found a significant reduction of the number of ramified
microglial cells in the GMwith increasing age, as well as a significantly
lower number of ramified microglial phenotype in the AD group.
Ramified microglia, which have thin, branched processes are thought
to be actively “surveying” changes in their environment.37,39 Previous
studies also found reduced ramified microglia in individuals with DS
relative to age-matched controls,31 and fewer ramified microglia
are also observed in individuals with non-DS dementia (including AD,
hippocampal sclerosis of aging, hippocampal sclerosis of agingwithAD,
and dementia with Lewy bodies) than age-matched controls without
dementia.38
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F IGURE 5 Group specific patterns in Iba1microglia staining. Representative images of microglia morphologies observed in the white (A) and
gray (B) matter of young controls (A1, B1), middle-aged controls (A2, B2), aged controls (A3, B3), Down syndrome (A4, B4), Down syndromewith
neuropathological Alzheimer’s disease (A5, B5), and AD (A6, B6), respectively. Scale: 50 μm
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Descriptions of rod-shaped microglia, which present elongated
nuclei, few processes, and are most notable in chronic disorders,
are sparse in the literature. Based on previous studies showing an
increase in rod-shaped microglia with age38,47 and the presence of
rod cells in the hippocampus of people with DS56 we hypothesized
that we would see an increase in rod-shaped microglia with age in our
controls and DS autopsy cases. However, we only found a significant
increase in rod-shaped microglia in our DSAD cohort in comparison
to AD. The function of these cells remains under investigation, but
it is believed that they could provide neuroprotection to neurons
and trophic support.57,58 The role of rod-shaped microglia in aging
and the development of AD in DS is still unclear and encourages
more studies; however, our findings suggest that DSAD is associated
with a microglial phenotype that distinguishes them from non-DS
cases.
Amoeboid microglia are most commonly found in the developing
brain, before transforming into ramified microglia.39,59 They have an
increased level of motility, facilitated by their reduced and retracted
processes, and are phenotypically very similar to macrophages found
in the rest of the body.60 It is still unknown whether these microglia
are senescing microglia found in the brain, or if they originate from
monocytes entering the brain in response to injury.37 We found that
our DSAD cases had significantly more amoeboid microglia than age
matched controls or young individualswithDS. It is possible thatmono-
cytes from the blood are entering the brains of people with DS as
vascular neuropathology may lead to small microhemorrhages in the
brain49,50 and the presence of more amoeboid microglial cells; how-
ever, further work needs to be done to explore the clinical significance
of amoeboidmicroglia in DSAD.
Finally, and most importantly, dystrophic microglia counts are sig-
nificantly increased in older individuals with DS (age effect), and in
AD. The concept of a hypofunctional microglia, as opposed to acti-
vated, came from morphological analysis of Iba1-positive microglia
in autopsy samples from aged humans, where dystrophic microglia
preceded neurofibrillary pathology in AD.61 This suggested that the
loss of microglial function might be as important as the activation
of a toxic, reactive cell. Other studies that aimed to quantify and
characterize microglial morphology in AD also found increased dys-
trophic cells.38,40,42,45 Individuals with DSAD showed a higher num-
ber of dystrophic microglia than the AD group, albeit their numbers
did not reach statistical difference. Additionally, young controls with
DS have high numbers of dystrophic microglia in the WM, suggesting
that this region in the DS brain is particularly vulnerable to degen-
eration, and that some aspects of aging might be accelerated in this
population.62,63 Dystrophic microglia have fragmented or “beaded”
processes that may be the result of microglial dysfunction or senes-
cence due to aging or AD neuropathology, and are thought of as
important markers for AD pathology. It is well accepted that human
microglial processes shorten with age, leading to a reduced arboriza-
tion area and reduced capacity for GM surveillance.27,51 Importantly,
tau-positive neurons are associated with dystrophic microglia, sup-
porting a fundamental role for lack of microglial support in the disease
progression.61
Overall, individuals with DS, particularly those with DSAD, have a
distinct microglial phenotype pattern. In DSAD, there is a shift toward
thepresenceof highernumbersof dystrophicmicroglial cells and fewer
ramified microglial cells suggesting fewer resting state microglia and
more damage to microglia, as well as increased amoeboid cells. Fur-
ther, individuals with DS appear to have important microglial changes
that could be related to the development and progression of AD. Our
data suggest that microglial changes progress gradually over time as
DS individuals are aging and, more importantly, provide specific infor-
mation related to the presence of AD in DS. These data reinforce the
differences in the neuroinflammation phenotype seen in individuals
with DS and, given the large variety of inflammatory genes located on
chromosome 21, suggest that these different gene expression profiles
could also be impacting the morphology of microglia cells, and conse-
quently, their response to the presence of AD pathology. Neuropatho-
logical observations from autopsy cases with DS allows us to directly
assess early events in AD, addressing a critical gap in our knowledge
regarding early events, which are targetable, in sporadic AD pathogen-
esis.
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